INOVIO is focused on rapidly bringing to market precisely designed DNA medicines to potentially treat and protect people from diseases associated with HPV, cancer, and infectious diseases. In the last several years INOVIO has had its data published in several prominent peer-reviewed medical journals including:
EClinicalMedicine
December 2020
Nature Communications
May 2020
The New England Journal of Medicine
October 2017
The Lancet Infectious Diseases
July 2019
The Journal of Infectious Diseases
March 2019
Filter by Category
Title | Disease Target | Product |
---|---|---|
Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT Molecular Therapy — November 2017 | Disease TargethTERT | ProductINO-5401 |
Highly Optimized DNA Vaccine Targeting Human Telomerase Reverse Transcriptase Stimulates Potent Antitumor Immunity Cancer Immunology Research — September 2013 | Disease TargethTERT | ProductINO-5401 |
A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity Molecular Therapy — February 2017 | Disease TargetWT1 | ProductINO-5401 |
CD8+ T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens Molecular Therapy — March 2020 | Disease TargetPSA | ProductINO-5151 |
Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses Human Vaccines — January 2011 | Disease TargetPSA, PSMA | ProductINO-5401 |
Title | Disease Target | Product |
---|---|---|
DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity JCI Insight — April 2019 | Disease TargetHER2 |
Title | Disease Target | Product |
---|---|---|
Electroporation delivery of DNA vaccines: prospects for success Current Opinion in Immunology — June 2011 | Disease TargetDelivery | ProductCELLECTRA® |
A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle Vaccine — September 2011 | Disease TargetDelivery | ProductCELLECTRA |
Integration of needle-free jet injection with advanced electroporation delivery enhances the magnitude, kinetics, and persistence of engineered DNA vaccine induced immune responses Vaccine — June 2019 | Disease TargetDelivery | ProductCELLECTRA |
© Copyright 2021 INOVIO Pharmaceuticals. All rights reserved.